PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the House Committee on Energy and Commerce.
Congressional Research Service
No official summary is available in the imported record yet.
People & committees
Rep. Dunn, Neal P. [R-FL-2] · R–FL
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Sep 28, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.10549 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.10549 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.10549 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.10549 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2026-09-24 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
The proposed Patients Choice in Specialty Pharmacy Act would restrict how health insurers and certain employer health plans direct patients to specialty pharmacies connected to them or their pharmacy benefit managers. For covered prescriptions, it would prohibit steering patients through higher charges, financial incentives, or administrative burdens. It would also require networks to accept pharmacies meeting specified qualifications, subject to misconduct and patient-safety exceptions. Self-insured group health plans would be excluded.
This Act may be cited as the Patients Choice in Specialty Pharmacy Act.
A group health plan (other than a self-insured group health plan) or a health insurance issuer offering group or individual health insurance coverage may not require, steer, or induce an enrollee in the plan or coverage to obtain a prescription drug for which benefits are available under the plan or coverage from an affiliated specialty pharmacy
Subject to paragraph (2), a group health plan (other than a self-insured group health plan) or a health insurance issuer offering group or individual health insurance coverage may not refuse to contract with, or otherwise exclude from the network of the plan or coverage, any specialty pharmacy that—
(2) Exclusion allowed for good cause
The bill would add a specialty-pharmacy choice section to the Public Health Service Act. Its restrictions would cover health insurers offering individual or group coverage and group health plans other than self-insured plans.
Subpart II of part A of title XXVII of the Public Health Service Act (42 U.S.C. 300gg–11 et seq.) is amended by adding at the end the following new section: 2730. Prohibition on limiting specialty pharmacy choice
A group health plan (other than a self-insured group health plan) or a health insurance issuer offering group or individual health insurance coverage
For prescriptions covered by the plan, the bill would prohibit charging patients more for using an unaffiliated specialty pharmacy. It would also prohibit discounts, rebates, or other financial incentives conditioned on using an affiliated pharmacy.
to obtain a prescription drug for which benefits are available under the plan or coverage from an affiliated specialty pharmacy, including by— (1) imposing higher cost sharing, including copayments, coinsurance, or deductibles, when such drug is dispensed by a specialty pharmacy that is not an affiliated specialty pharmacy; (2) offering a discount, rebate, or other financial incentive that is conditioned on the enrollee obtaining such drug from an affiliated specialty pharmacy
Plans and insurers could not steer patients to affiliated specialty pharmacies by imposing penalties, delays, or other administrative burdens on patients using another specialty pharmacy or on clinicians directing patients there.
(3) imposing a penalty, delay, or other administrative burden on an enrollee (or the health care provider prescribing such drug to such enrollee) who obtains (or directs such enrollee to obtain) such drug from a specialty pharmacy that is not an affiliated specialty pharmacy.
Subject to the stated exceptions, a specialty pharmacy would have to be admitted to a network if it is licensed and in good standing where it dispenses the drug, accepts uniformly applied participation terms, and is willing to accept the same payment rates as other specialty pharmacies in that network.
may not refuse to contract with, or otherwise exclude from the network of the plan or coverage, any specialty pharmacy that— (A) is licensed and in good standing under the laws of the State in which it dispenses the drug; (B) agrees to meet all terms and conditions of network participation that are uniformly applied to all specialty pharmacies in the network of the plan or coverage, which may include, at the option of the plan or issuer, a requirement that the specialty pharmacy maintain accreditation from a nationally recognized accrediting organization; and (C) is willing to accept the same reimbursement rates as other specialty pharmacies in the network of the plan or coverage.
Plans and insurers could choose to require accreditation—recognition by an accrediting organization—as a uniformly applied network condition. For this purpose, the bill names only the Joint Commission on Health Care Organizations, the Utilization Review Accreditation Commission, and the Accreditation Commission for Health Care.
all terms and conditions of network participation that are uniformly applied to all specialty pharmacies in the network of the plan or coverage, which may include, at the option of the plan or issuer, a requirement that the specialty pharmacy maintain accreditation from a nationally recognized accrediting organization
The term nationally recognized accrediting organization means— (A) the Joint Commission on Health Care Organizations; (B) the Utilization Review Accreditation Commission; or (C) the Accreditation Commission for Health Care.
The network-admission requirement would not apply to a pharmacy convicted of a federal or state offense involving fraud or abuse, or disciplined by a state pharmacy board for activities involving fraud or abuse.
The requirement under paragraph (1) shall not apply
(A) such specialty pharmacy— (i) has been convicted under Federal or State law of an offense related to fraud or abuse; or (ii) has been subjected to disciplinary action by a State board of pharmacy in connection with activities related to fraud or abuse
A pharmacy could also be excluded if it had been excluded or suspended from Medicare or a state health care program covered by the referenced statutory definition. Separately, exclusion would be allowed if the plan or insurer demonstrated to a state pharmacy board or another competent regulator that contracting with the pharmacy posed an imminent risk of patient harm.
(B) such specialty pharmacy has been excluded or suspended from participation in the Medicare program under title XVIII of the Social Security Act, or a State health care program (as defined in section 1128(h) of such Act); or (C) the plan or issuer demonstrates to the State board of pharmacy or other competent regulatory authority that contracting with such specialty pharmacy poses an imminent risk of patient harm.
An affiliated specialty pharmacy would include one in which the plan, insurer, or its pharmacy benefit manager has an ownership or control interest under a referenced legal definition. It would also include a pharmacy under their direct or indirect operational, financial, or managerial control. A pharmacy benefit manager is an entity providing pharmacy-benefit management services for the plan or insurer.
a specialty pharmacy— (A) with respect to which such plan or issuer (or an entity providing pharmacy benefit management services on behalf of such plan or issuer) is a person with an ownership or control interest (as defined in section 1124(a)(3) of the Social Security Act); or (B) with respect to which such plan or issuer (or an entity providing pharmacy benefit management services on behalf of such plan or issuer) otherwise exercises (directly or indirectly) operational, financial, or managerial control.
A specialty pharmacy would have to be licensed and in good standing where it dispenses drugs. It would have to dispense drugs needing more handling, storage, administration, or monitoring than most retail prescriptions, or drugs treating complex, expensive, or rare conditions. It would also need the ability, consistent with state law, to provide appropriate clinical and patient support, potentially including education, help following treatment, coordination with prescribers, and monitoring for harmful reactions.
The term specialty pharmacy means a pharmacy that— (A) is licensed and in good standing under the laws of the State in which it dispenses drugs; (B) dispenses drugs that— (i) require handling, storage, administration, or monitoring exceeding that customarily required for most retail prescription drugs; or (ii) are used in the treatment of complex, expensive, or rare health conditions; and (C) has the capability, consistent with applicable State law, to provide clinical and patient support services appropriate to the dispensing of drugs described in subparagraph (B), which may include patient education, adherence support, care coordination with the prescribing provider, and monitoring for adverse events.
The proposed changes would apply to plan years beginning on or after January 1, 2029.
The amendments made by this section shall apply with respect to plan years beginning on or after January 1, 2029.
The supplied official-actions snapshot, updated September 28, 2026, records introduction in the House and referral to the House Committee on Energy and Commerce on September 24, 2026. It does not establish subsequent legislative action or enactment.
Source snapshot updated 2026-09-28T15:24:19Z. 2026-09-24: Referred to the House Committee on Energy and Commerce. 2026-09-24: Introduced in House
A closer look
Reviewed version: Introduced in House · 2026-09-24. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
None identified in the reviewed text
No unrelated provision or policy change attached to appropriations was identified in the complete supplied introduced-text version. This conclusion does not extend to other versions or accompanying materials.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for particular recipients or places was identified in the complete supplied introduced-text version. This does not establish absence in other versions or accompanying materials.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
Findings to examine
The supplied text gives a narrowly defined set of organizations recognition relevant to an optional network qualification. This classification does not establish financial gain or improper purpose.
The bill limits the recognized accrediting organizations for an optional specialty-pharmacy network requirement to three named entities: the Joint Commission on Health Care Organizations, the Utilization Review Accreditation Commission, and the Accreditation Commission for Health Care. This gives those organizations a specific recognition advantage within the bill's pharmacy-access policy. Plans and insurers could choose whether to require that accreditation.
which may include, at the option of the plan or issuer, a requirement that the specialty pharmacy maintain accreditation from a nationally recognized accrediting organization
The term nationally recognized accrediting organization means— (A) the Joint Commission on Health Care Organizations; (B) the Utilization Review Accreditation Commission; or (C) the Accreditation Commission for Health Care.
Full text preserved for this analysis. Legislative record snapshot: Sep 28, 2026. How PlainBill uses AI